Selective non-benzodiazepine anxiolytic with sigma-1 receptor chaperone agonism and multi-target neuroprotective activity
A 2-mercaptobenzimidazole derivative developed at the V.V. Zakusov Research Institute of Pharmacology and registered in Russia as a non-sedating anxiolytic, distinguished from benzodiazepines by absence of dependence liability and from buspirone by sigma-1 receptor chaperone agonism as the principal molecular mechanism.
Abstract
Afobazole (INN fabomotizole; development code CM-346; CAS 173352-21-1) is a 2-mercaptobenzimidazole anxiolytic synthesized and pharmacologically characterized at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences under the direction of Academician S.B. Seredenin. The compound was registered in the Russian Federation in 2006 for the treatment of generalized anxiety disorder and adjustment disorders, and was assigned the International Nonproprietary Name fabomotizole by the World Health Organization in 2012. Structurally, afobazole is 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole, a synthetic benzimidazole bearing a thioether-linked morpholine side chain and an ethoxy substituent on the aromatic ring. The molecular formula is C15H21N3O2S (free base, molecular weight 307.41 g/mol), and the compound is supplied pharmaceutically as the dihydrochloride salt (C15H23Cl2N3O2S, molecular weight 380.33 g/mol).
The pharmacological profile of afobazole is multi-target. Radioligand binding studies have identified the sigma-1 receptor chaperone protein (Sigma1R; Ki approximately 5.9 micromolar), NRH:quinone reductase 2 (NQO2, also designated the MT3 melatonin binding site; Ki approximately 0.97 micromolar), monoamine oxidase A (MAO-A regulatory site; Ki approximately 3.6 micromolar), and the melatonin MT1 receptor (Ki approximately 16 micromolar) as the principal molecular targets [1, 2]. The sigma-1 receptor interaction is the best-characterized mechanism: afobazole acts as a Sigma1R agonist, promoting dissociation of the Sigma1R-BiP complex at the endoplasmic reticulum membrane and downstream modulation of calcium signaling, inositol 1,4,5-trisphosphate receptor function, and expression of neurotrophic factors including nerve growth factor and brain-derived neurotrophic factor [3, 4]. The anxiolytic effect is blocked by selective Sigma1R antagonists (BD-1047, NE-100) in rodent behavioral models, confirming the dependence of the therapeutic activity on Sigma1R engagement [5, 6].
Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 0.85 hours), pronounced first-pass hepatic metabolism (oral bioavailability approximately 44 percent), and a short plasma elimination half-life (approximately 0.82 hours) [9]. Despite the short systemic half-life, the anxiolytic effect persists substantially beyond the plasma residence of the parent compound, a pharmacodynamic feature attributed to the slow dissociation kinetics of the Sigma1R chaperone complex and to the sustained expression of downstream neurotrophic mediators.
The clinical evidence base comprises several Russian multicenter trials. The principal registration study was a randomized, double-blind, active-controlled trial of 150 patients with generalized anxiety disorder or adjustment disorders comparing afobazole (30 mg/day) to diazepam (30 mg/day) for 30 days; afobazole produced greater reduction in Hamilton Anxiety Rating Scale total score than diazepam (mean difference 2.93 points; p = 0.01), with 15 adverse events in the afobazole group versus 199 in the diazepam group, and no withdrawal syndrome on discontinuation [8]. Additional studies have evaluated afobazole in somatoform disorders, irritable bowel syndrome, premenstrual syndrome, alcohol withdrawal, and tobacco cessation, with consistent evidence of anxiolytic efficacy and favorable tolerability [10, 11, 12].
Preclinical research has extended the pharmacological profile well beyond anxiolysis. Afobazole produces Sigma1R-dependent neuroprotection in rat models of ischemic stroke (middle cerebral artery occlusion), with reduced infarct volume and improved neurological outcomes when administered up to 24 hours post-occlusion [13, 14]. In the 6-hydroxydopamine mouse model of Parkinson’s disease, afobazole at 2.5 mg/kg intraperitoneally for 14 days restored striatal dopamine content, preserved tyrosine hydroxylase-positive neurons in the substantia nigra, and normalized motor coordination; these effects were abolished by the Sigma1R antagonist BD-1047 [15, 16]. Cardioprotective activity has been demonstrated in models of isoproterenol-induced myocardial injury, chronic heart failure, and alcoholic cardiomyopathy, with attenuation of pathological remodeling, preserved inotropic function, and reduced brain natriuretic peptide levels [17, 18, 19]. Angiogenic effects have also been reported [20].
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.